The global Chronic Rhinosinusitis Market was valued at USD 2132.5 million in 2019 and is expected to reach USD 3508.0 million by 2027, at a CAGR of 7.4%, According to the current analysis of Emergen Research.
The global Chronic Rhinosinusitis Market was valued at USD 2132.5 million in 2019 and is expected to reach USD 3508.0 million by 2027, at a CAGR of 7.4%, According to the current analysis of Emergen Research. The rising prevalence of chronic rhinosinusitis (CRS) is the major factor driving market growth. According to the American Academy of Otolaryngology Head and Neck Surgery Foundation, in the U.S., CRS is one of the most common conditions, affecting around 37 million adults annually. Moreover, the growing awareness about CRS and its available treatments is another significant factor anticipated to fuel market growth in the coming years. However, the availability of alternative therapies is expected to restraint market growth to some extent over the forecast period. Development and manufacture of proficient sinusitis drugs is a challenge for key players in the global chronic rhinosinusitis market. Moreover, stringent approval process and time-consuming clinical trials are some of the major factors hampering the growth of this market.
Chronic rhinosinusitis (CRS) is a persistent inflammation of the paranasal sinuses that affects the quality of life of patients. CRS is classified into two types: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). The most common symptoms of CRS include facial pain, nasal obstruction, and runny nose. Nasal corticosteroids are the most commonly prescribed drugs for the treatment of CRS.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/74
In sinusitis, the air-filled cavities present behind the forehead, cheekbones, and around the eyes get inflamed due to viral or bacterial infection. Swelling in these cavities blocks the drainage of mucus, causing pressure and pain in the forehead and cheeks. The most common symptoms of sinusitis include runny nose, fever, facial pain & pressure, and thick yellow or green mucus discharge.
Xolair (Omalizumab) manufactured by Novartis is an injectable biologic medication indicated for the treatment of chronic spontaneous urticaria (CSU) in adults and children 12 years and older. The drug works by targeting IgE, a protein that is responsible for the development of allergy symptoms. Xolair was approved by the FDA in 2003 and is currently marketed in over 75 countries worldwide.
Some Key Highlights from the Report
- The antibiotics product segment is expected to register the fastest revenue CAGR during the forecast period due to the launches of products such as Mupirocin and Polymixin B. The nasal sprays segment is expected to grow at the highest CAGR during the forecast period due to its convenience of use, easy availability, and wide range of indications.
- The Immune deficiency disease segment is expected to register the fastest revenue CAGR during the forecast period due to the increasing awareness about the disease and its treatments. Also, the increasing number of people suffering from chronic rhinosinusitis is propelling the growth of this segment.
- The Hospital Pharmacies segment is expected to register the fastest revenue CAGR during the forecast period due to the preference for hospital-based treatment, growing awareness about self-medication, and the availability of advanced facilities at hospitals.
- Owing to favourable reimbursement policies and the availability of effective treatments, North America is expected to dominate the chronic rhinosinusitis market over the forecast period. According to the National Institute of Allergy and Infectious Diseases (NIAID), in 2016, around 16.4 million adults aged 18 years or older were diagnosed with CRS in the U.S. Increasing number of clinical trials in the U.S. is also expected to propel market growth over the forecast period.
- Asia Pacific is expected to witness fastest growth over the forecast period owing to the large patient pool and untapped potential in countries such as China and India. In addition, factors such as government initiatives to improve healthcare infrastructure and rising awareness about CRS is also expected to boost market growth.
- Key market companies studied and profiled for this research include AstraZeneca, Bayer AG, Ivax Pharmaceuticals, Pfizer, Novartis Pharmaceuticals Corporation, Sanofi, Sunovion Pharmaceuticals, Cipla, Smith & Nephew, Medtronic, SinuSys Corporation, Olympus Corporation and Acclarent among other companies.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/chronic-rhinosinusitis-market
Emergen Research have segmented Chronic Rhinosinusitis Market on the basis of product, disease type, distribution channel and region:
Product Outlook (Revenue in Million USD; 2017–2027)
- Steroids
- Topical Nasal Steroid
- Systemic Steroids
- Nasal Irrigation
- Hypertonic and Isotonic Saline
- Steroid Nasal Irrigation
- Topical Antibiotic Therapy
- Surgical Based
- Ethmoidectomy
- Endoscopic Intranasal Intervention
- Others
- Antibiotics
- Amoxicillin-Clavulanate
- Clindamycin
- Sulfamethoxazole
- Levofloxacin
- Macrolide Therapy
- Antifungal Therapy
Disease Outlook (Revenue in Million USD; 2017–2027)
- Anatomical Differences
- Nasal Tumors
- Mucosal Edema
- Non-Allergic Rhinitis
- Immune Deficiency
- Other
Distribution Channel (Revenue in Million USD; 2017–2027)
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Other
Regional Outlook (Revenue in Million USD; 2017–2027)
- North America
- U.S
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/74
Explore More Reports Emergen Research:
Healthcare Business Intelligence Market
Healthcare IT Integration Market
Operating Room Integration Systems Market
Medical Device Connectivity Market
Patient Registry Software Market
Automotive Intelligent Lighting Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-chronic-rhinosinusitis-market